Equities analysts expect that RedHill Biopharma Ltd (NASDAQ:RDHL) will post $2.73 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for RedHill Biopharma’s earnings. The lowest sales estimate is $2.60 million and the highest is $2.90 million. RedHill Biopharma reported sales of $480,000.00 in the same quarter last year, which indicates a positive year over year growth rate of 468.8%. The company is scheduled to report its next quarterly earnings report on Tuesday, July 24th.
On average, analysts expect that RedHill Biopharma will report full-year sales of $11.55 million for the current year, with estimates ranging from $10.97 million to $12.40 million. For the next year, analysts forecast that the firm will post sales of $18.20 million per share, with estimates ranging from $15.00 million to $21.39 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that follow RedHill Biopharma.
RedHill Biopharma (NASDAQ:RDHL) last released its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported ($0.50) earnings per share for the quarter, hitting the consensus estimate of ($0.50). The firm had revenue of $2.45 million for the quarter, compared to analyst estimates of $2.14 million. RedHill Biopharma had a negative net margin of 726.64% and a negative return on equity of 114.27%.
Several research firms recently weighed in on RDHL. Zacks Investment Research upgraded shares of RedHill Biopharma from a “hold” rating to a “buy” rating and set a $6.75 price objective on the stock in a research note on Saturday, May 12th. Nomura began coverage on shares of RedHill Biopharma in a research note on Friday, January 26th. They set a “buy” rating and a $18.00 price objective on the stock. HC Wainwright set a $36.00 price objective on shares of RedHill Biopharma and gave the stock a “buy” rating in a research note on Wednesday, May 9th. Finally, ValuEngine lowered shares of RedHill Biopharma from a “sell” rating to a “strong sell” rating in a research note on Tuesday, May 8th. Two equities research analysts have rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $19.95.
Large investors have recently made changes to their positions in the business. Citadel Advisors LLC acquired a new stake in shares of RedHill Biopharma in the fourth quarter valued at approximately $170,000. ARK Investment Management LLC acquired a new stake in shares of RedHill Biopharma in the fourth quarter valued at approximately $149,000. Sabby Management LLC acquired a new stake in shares of RedHill Biopharma in the fourth quarter valued at approximately $110,000. Meitav Dash Investments Ltd. acquired a new stake in shares of RedHill Biopharma in the fourth quarter valued at approximately $244,000. Finally, Creative Planning acquired a new stake in shares of RedHill Biopharma in the fourth quarter valued at approximately $722,000. Institutional investors own 20.03% of the company’s stock.
RDHL traded up $0.08 on Wednesday, hitting $7.08. 69,999 shares of the company’s stock were exchanged, compared to its average volume of 99,159. The firm has a market cap of $148.91 million, a price-to-earnings ratio of -2.72 and a beta of 0.69. RedHill Biopharma has a twelve month low of $4.30 and a twelve month high of $11.25.
RedHill Biopharma Company Profile
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on the development and commercialization of late clinical-stage, proprietary, and in-licensed/acquired drugs for the treatment of gastrointestinal and inflammatory diseases, and cancer. The company commercializes three gastrointestinal products in the United States, such as Donnatal, a prescription oral adjunctive drug used in the treatment of irritable bowel syndrome (IBS), and acute enterocolitis and duodenal ulcers; EnteraGam, a prescription medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools; and Esomeprazole Strontium Delayed-Release Capsules 49.3 mg, a prescription proton pump inhibitor drug product indicated for adults for the treatment of GERD, risk reduction of NSAID-associated gastric ulcer, Helicobacter pylori eradication to reduce the risk of duodenal ulcer recurrence, and for pathological hypersecretory conditions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.